Beta Bionics, Inc.
BBNXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring. With a market capitalization of $518.3M, it sits in small-cap territory. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Market Cap
$518.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.87
EPS (TTM)
$-1.37
EPS (Fwd)
$-2.39
ROE
-22.7%
ROA
-15.0%
Cash
$199.5M
Total Debt
$6.9M
Free CF
-$44.1M
52W Change
-24.3%
Annual Financials
Cash vs Debt
With $199.5M in cash and $6.9M in debt, BBNX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$44.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -22.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $179K (2022) to $100.3M (2025), reflecting a 55906% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BBNX.